BHCM
VRDN icon

Brevan Howard Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Brevan Howard Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$358K Buy
19,501
+3,986
+26% +$64.2K ﹤0.01% 1604
2026
Q1 		$303K Sell
15,515
-2,035
-12% -$60.4K ﹤0.01% 1607
2025
Q4 		$546K Buy
+17,550
New +$481K 0.01% 1065
2025
Q1 		– Sell
-13,473
Closed -$258K – 1490
2024
Q4 		$258K Buy
+13,473
New +$293K ﹤0.01% 829

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Brevan Howard Capital Management's VRDN Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Viridian Therapeutics (VRDN) stake by 26% in Q2 2026, buying an estimated $64.2K and bringing the position to 19,501 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #1604.

Brevan Howard Capital Management first reported a position in VRDN in Q4 2024 and has held it in 4 quarters since. The position peaked at $546K in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Brevan Howard Capital Management held 19,501 shares of Viridian Therapeutics worth $358K as of Q2 2026.
  • Brevan Howard Capital Management bought 3,986 Viridian Therapeutics shares in Q2 2026, an estimated $64.2K.
  • Viridian Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1604 holding.
  • Brevan Howard Capital Management first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Brevan Howard Capital Management's Viridian Therapeutics position peaked at $546K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.